PTC Harmony 96 Thermal Cycler
HERCULES, Calif.—April 28, 2026—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of the PTC Harmony Thermal Cycler line, designed to offer broader access to optimized workflows for PCR applications such as sequencing, cloning, and genotyping.
PTC Harmony 96 and PTC Harmony Deepwell are the latest additions to Bio-Rad's next generation of conventional PCR thermal cyclers. Designed for a broader range of budgets, the PTC Harmony Thermal Cyclers provide the same thermal performance as the PTC Tempo line in a streamlined design with an intuitive user interface, manual lid operation, and flexible connectivity options, simplifying protocol management. The PTC Harmony line expands Bio-Rad’s reliable thermal cycler portfolio to scientists seeking faster PCR runs, higher performance, and accuracy in a simplified workflow.
“Tailored to academic and biopharma customers interested in simplified and affordable, high-performance devices, the new line of PTC Harmony Thermal Cyclers delivers the same reliability and high quality that Bio-Rad has been providing for over 35 years,” said Stephen Kulisch, Vice President of Genomics Product Management, Bio-Rad. "Leveraging our engineering expertise, we continue to develop and manufacture robust and efficient thermal cyclers, demonstrating our ongoing commitment to meeting the needs of all scientists."
Visit www.bio-rad.com/PTC-Harmony to learn more about the PTC Harmony Thermal Cyclers.
Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. All trademarks used herein are the property of their respective owner. © 2026 Bio-Rad Laboratories, Inc.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,400 employees and $2.6 billion in revenues in 2025. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations, global economic and geopolitical conditions, tariffs or other trade barriers, reductions in government funding or capital spending of our customers, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contacts:
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
Katrina_academia@bio-rad.com
Zyme Communications
Dr. Maria Spyrou maria.
spyrou@zymecommunications.com
To opt out from receiving press releases from Zyme Communications, please e-mail info@zymecommunications.com. To view our privacy policy, click here.